Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
Nature – The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
Clinical factors associated with an increased risk of psychological distress included younger age, female sex, advanced pathological/tumor stage, and preoperative setting.
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients…
Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.
This report was compiled by NORC at the University of Chicago on behalf of the Consumer Representatives to the NAIC. The report examines the current…
Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing…
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
An abstract is unavailable.
A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina…
